tgAAC 94

Drug Profile

tgAAC 94

Alternative Names: rAAV2-TNFR:Fc; tgAAC11; tgAAC94; tgAAV-TNFR:Fc; TNFR:Fc gene therapy

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targeted Genetics
  • Developer AmpliPhi Biosciences Corporation
  • Class Antirheumatics; Gene therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences
  • 11 Nov 2010 This programme is still suspended
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top